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bstract
Dipeptidyl peptidase IV, a cell membrane surface protease also known as CD26 (CD26/DPPIV), is known to play multiple functions in
uman organism, where it is largely expressed, for instance, in the development of human cancer and metastasis as well as in chemotherapy
esponse.
The objective of this work was to study the CD26 membrane expression and DPPIV activity in T-acute leukaemia cell lines (CEM and
OLT3) in culture, in order to observe the modification of its expression under the 8-azaguanine treatment.
Cell line samples were incubated, some without different azaguanine concentration and others with, ranging from 10 to 100M. Cell
urface CD26 expression has been identified by flow cytometry and DPPIV activity, in cultured medium, was fluorimetrically measured.
Results we have observed showed that 8-azaguanine induced a decrease in cell viability in a dose, time and cell type dependent manner
ith MOLT3 cells being the most sensitive to 8-azaguanine citotoxic effects (24 h IC50: ±10M) when compared with CEM cells (24 h
C50: ±100M).
In the same experimental conditions, MOLT3 cell treated with 8-azaguanine shows an increase in CD26 expression (MIF) compared with
hat of CEM cell submitted to the same conditions (65.4 ± 1.3 versus 18.7 ± 1.7). DPPIV activity in culture medium supernatant of CEM
ersus MOLT3 controls cells (1.91 ± 0.43 versus 2.06 ± 0.50) and of CEM versus MOLT3 treated cells (2.10 ± 0.16 versus 1.89 ± 0.04) did
ot show a significant difference.
These preliminary results suggest that 8-azaguanine stimulates CD26 expression which may be related to cellular sensitivity to 8-azaguanine.
2006 Elsevier Ireland Ltd. All rights reserved.
i
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. IntroductionCell surface-associated peptidases play important roles in
uman organism where they are largely distributed. They are
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oi:10.1016/j.pathophys.2006.09.003nvolved in many physiological processes ranging from mor-
hogenesis and tissue differentiation to the general regulation
f haemostasis. Some of these enzymes also appear to be
unctionally involved in cell activation and proliferation as
ell as in cancer cell growth and metastasis [1,2].
Among the membrane-associated peptidases is the serine
ctopeptidase dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5)
lso known as the surface antigen CD26, a T lymphocyte
ctivation marker [3].
Since its first description, by Hopsu-Havu and Glenner
n 1966, it has been considered as a unique peptidase that
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leaves dipeptides from the NH2-terminus of proteins having
roline, hidroxiproline or alanine residues at the penultimate
osition, with the highest efficiency observed with proline
esidues [4,5].
CD26 is constitutively expressed in a variety of differ-
nt tissues, e.g. intestine epithelial cells and kidney proximal
ubules [6,7,8]. DPPIV is involved in the mechanisms of
embrane protein turnover, glycosylation events, membrane
olarization, in cell adhesion events and in immune response
9,10].
Depending on its cellular localization and cell type
xpressing CD26/DPPIV, it is a multifunctional molecule
hat interferes with many immune functions, both in vitro
nd in vivo. In addition to its membrane-associated form,
D26/DPPIV is also present as a soluble exopeptidase
n various body fluids, such as plasma, serum and urine
4,11–15].
Independently of its peptidase activity, CD26/DPPIV is
ssociated to other molecules on the cell surface such as
denosine deaminase (ADA) and CD45. It has been shown
o be physically associated with ADA in the T-lymphocytes
urface, thus protecting the cell from adenosine-mediated
nhibition of proliferation. It is also associated with CD45, a
ell surface phosphotyrosine phosphatase, involved in signal
ransduction. In addition, it has also been proposed that CD26
s involved in the pathophysiology of the acquired immune
eficiency syndrome (AIDS) [11–13,16–22].
Both CD26/DPPIV features, as a membrane antigen and
s a peptidase, contribute to the co-stimulator function of
D26 in T-cell activation and apoptosis events. However, the
D26/DPPIV role in these events is still unclear [13,23,24].
CD26/DPPIV is involved in the control of cell growth
nd differentiation by controlling the access of mitogenic
eptides to their receptors on the cell membrane. Abnor-
alities in its expression pattern could result in altered
eptide activity, which may contribute to neoplastic trans-
ormation, cancer progression and therapeutic response
25,26].
The potential contribution of CD26/DPPIV in pathophys-
ological processes of cancer development, namely haemato-
ogical cancer, has been studied. Some studies demonstrated
hat it is an enzyme marker of diagnostic value in the lym-
hoproliferative diseases of T-cell origin [27–29]. There is
lack of information regarding the relationship between the
D26/DPPIV expression and complete phenotypic features
f T-cells acute leukaemia. Although some studies reported
hat CD26 was mostly expressed on CD30 anaplastic large
ell lymphoma (ALCL), and mainly in T-cell acute lym-
hoblastic leukaemia (T-cell ALL), non-Hodgkin’s B cell
ymphomas did not express CD26.
The exact picture of all biological functions of CD26/
PPIV is difficult to know. For example, in therapeutic strate-
ies, one knows relatively little about the relationship of
D26/DPPIV expression and chemotherapy response.
The objective of conventional cancer chemotherapy is
he destruction of cancer cells by disrupting its normal
2
wiology 14 (2007) 3–10
tructure. With this purpose, the nucleoside analogues have
een used in therapeutic protocols of ALL. 8-Azaguanine
s a purine analogue that shows antineoplastic activity. It
unctions as an antimetabolite and easily incorporates into
ibonucleic acids, interfering with normal biosynthetic path-
ays, thus inhibiting cellular growth. However, the develop-
ent of chemotherapy resistance is an obstacle to successful
eukaemia chemotherapy; therefore, identification of new
otential targets for cancer therapy is essential.
.1. Objectives
CD26/DPPIV has established relevance as a modulator of
ell activity. Little is known about its role in chemotherapy
esponse. The aim of this work was to determine both the
xpression of CD26 on cell surface of acute leukaemia cell
ines in culture (CEM and MOLT3), and the DPPIV activ-
ty (in culture medium supernatant, collected from cellular
ultures) after 8-azaguanine treatment.
. Materials and methods
.1. Cell culture
The CEM-CCRF and MOLT3 cells (acute lymphoblastic
eukaemia T cells) were supplied by American type collection
ATCC), Rockeville, USA. They were maintained in cul-
ure in RPMI-1640 medium (l-glutamine 2 mM, HEPES-Na
0 mM, NaHCO3 2 g/L, penicillin 100 U/mL and strepto-
ycin 100g/mL, pH 7.4) (Sigma®), supplemented with
0% foetal calf serum (FCS, GIBCO®) in 5% CO2 atmo-
phere, at 37 ◦C temperature. Cells were incubated in the
bsence and in the presence of increasing 8-azaguanine
Sigma®) concentrations, ranging from 25 to 200M. Cul-
ure medium supernatant and cell samples were collected to
erform the assays/analysis.
.2. Proliferation, viability and cell morphology
After 24, 48 and 72 h of incubation time, cells were har-
ested and assessed for proliferation, viability and cell mor-
hology. The mentioned analysis was performed in triplicate.
cell preparation without 8-azaguanine treatment was used
s control.
Cell proliferation was accessed by counting in a Neubauer
hamber; cell viability was estimated by trypan blue exclu-
ion; and, cell morphology was evaluated by light micro-
copic examination of May-Gru¨enwald-Giemsa stained cells,
sing a microscope Leitz Dialux 20 fitted with a photographic
hamber..3. Flow cytometry analysis
Monoclonal antibodies directly conjugated were used
ith one of the following fluorochromes: fluoresceine
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tive effect with lower 8-azaguanine concentrations. Actually
after 24 h of treatment with 8-azaguanine the IC50 for CEM
cell line is about 100M while for MOLT3 cell line the IC50
is about 10M, as it can be observed in Fig. 1A and B.
Fig. 1. Dose response curves: CEM (A) and MOLT3 (B) cell viability curves.
The cell lines were cultured at 37 ◦C in RPMI 1640 medium, and incu-
bated in an initial concentration of 0.3 × 106 cells/mL for CEM cells, and
of 0.6 × 106 cells/mL for MOLT3 cells. Cells were incubated in the absence
and in the presence of different 8-azaguanine concentrations, as indicatedM. Dourado et al. / Pat
sothiocyanate (FITC), phycoerythrin (PE). Flow cytome-
ry was performed using a FACSCaliburTM from Becton
ickinson®, collecting 10,000 events by acquisition.
Detection of apoptosis and necrosis was analysed by
nnexin V (AV-FITC) and propidium iodide (PI) staining.
fter incubation in the absence or in the presence of 8-
zaguanine, cells were washed (centrifuged at 300 × g during
min) and incubated for 10 min at 4 ◦C in 440L Annexin
uffer, from Immunotech®, containing 5L AV-FITC and
L PI. Then cells were washed and re-suspended in phos-
hate buffered saline (PBS) until analysis.
For CD26 analysis, 1 × 106 cells (incubated in the
reviously referred conditions) were centrifuged and incu-
ated for 10 min at room temperature, with 1g anti-
D26 (PE) from Immune Source®. After that, cells were
ashed with PBS, by centrifugation at 300 × g during
min and analysed on FacsCaliburTM from Becton Dick-
nson, collecting 10,000 events by acquisition, in order to
ssess the percentages of the total number cells express-
ng CD26 and the number of molecules of CD26 expressed
y each cell mean fluorescence intensity (MFI). This
alue represents the medium fluorescence intensity detected
n the cells, which is proportional to the number of
olecules labelled by the monoclonal antibody. Nega-
ive controls were established with isotype immunoglobin
(Ig G), IgG1 and IgG2b, submitted to the same
rocedures.
.4. Dipeptidyl peptidase IV (DPPIV) activity
DPPIV activity in culture medium supernatant was mea-
ured by a fluorimetric assay as previously described by
harpe´ et al. [30].
DPPIV catalyses the cleavage of the fluorogenic sub-
trate Gly-Pro-4-Me-2-NA, Sigma–Aldrich Co. (St. Louis,
3178-MO, USA), releasing a highly fluorescent molecule:
-Me-2-NA. For the substrate solution, 20 mmol/L, 7.37 mg
f substrate was dissolved in 1 mL of DMSO. This solution
as stored at 4 ◦C.
Standard solution, 4-Me-2-NA was acquired from
achem Feinchemikalien AG (Budendorf-Switzerland). The
tock solution was 50 mmol/L 4-Me-2-NA in DMSO. Before
se, it was dissolved as required with stopping solution.
Incubation buffer is a 50 mmol/L Tris–HCL solution, pH
.3 adjusted at room temperature, stored at 4 ◦C. Stopping
olution is a 100 mmol/L citrate solution, pH 4.0, adjusted at
oom temperature and stored in the refrigerator at 4 ◦C.
The assays’ fluorescence intensity was measured with
JASCO FP-777 spectrofluorimeter, with a quartz cell, at
40 nm of excitation (Ex) and at 425 nm of the emission (Em)
avelengths.
DPPIV activity has been expressed in units/litre (U/L).
ne unit (U) of DPPIV activity was defined as the enzyme
ctivity that produces 1mol of 4-Me-2-NA in 1 min under
he reaction conditions.
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.5. Statistical analysis
Student’s t-test was used to determine the statistical sig-
ificance, considering a p-value of ≤0.05 significance.
. Results
In order to analyse the effects of the chemotherapeutic
gent 8-azaguanine in cell viability, different specimens of
EM and MOLT3 cells were incubated in the absence and in
he presence of various 8-azaguanine concentration (ranging
rom 10 to 100M). Data represent the mean ± S.D. of three
o six separate experiments. The results show that cell viabil-
ty decrease after incubation with 8-azaguanine, in a dose and
ime dependent manner, as represented in Fig. 1A, for CEM
ell line, and Fig. 1B, for MOLT3 cell line. However, MOLT3
ells seem to be more sensitive to 8-azaguanine than CEM
ells, since in the former, we observe the same antiprolifera-n the figure: 25, 50, 100 and 200M for CEM and 10, 25, 50 and 100M
or MOLT3, during 24, 48, 72 and 96 h. Cell viability was determined by
rypan blue exclusion each 24 h. Both cell lines demonstrate a significant
ecrease of cell viability, after azaguanine-incubation. Data represent the
eans ± S.D. of three to six separate experiments.
6 M. Dourado et al. / Pathophysiology 14 (2007) 3–10
Fig. 2. Cellular morphology analysis of May-Gru¨nwald-Giemsa stained
cells (500×), before (A) and after (B) 8-azaguanine treatment. The figure
represents the CEM cell line as an example of what it was done in the
study. (A) shows the normal morphology of human leukaemia T-cell line;
(B) shows morphological changes after 8-azaguanine treatment. Morpholog-
ical changes are related to apoptotic cell death, namely cellular shrinking,
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Fig. 3. Evaluation of cellular death by flow cytometry. Cell lines were incu-
bated in the absence (control, A) and in the presence (B) of 8-azaguanine.
Cell death was detected by Annexin V/propidium iodide (AV/IP) staining
and analysed by flow cytometry. Live cells (L), are Annexin V/propidium
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The DPPIV activity measured in cell culture medium col-embrane blebs, DNA fragmentation, indicated by the arrows.
In Fig. 1A, it is possible to observe that CEM cell viability,
long the time of incubation with different 8-azaguanine con-
entrations, decreases to a value inferior to 20%. Fig. 1B rep-
esents the results of MOLT3 cells treated with 8-azaguanine,
n different concentrations and different time of incubation.
decrease in cell viability (about 20%) was also observed. In
oth cell lines, the observed effects are time and dose depen-
ent.
The observed decrease of cell viability is related to an
ncrease in cell death. Fig. 2A shows the morphological char-
cteristics of control cells. Fig. 2B shows the morphological
haracteristics of incubated cells with 8-azaguanine demon-
trating apoptotic cell death, namely cellular shrinking,
embrane blebs and DNA fragmentation (indicated by the
rrows). The morphological changes observed in microscopic
lides are in agreement with those observed by flow cytometry
nalysis using AV/PI staining as they are represented in Fig. 3.
ig. 3A, which represents the control cells, shows that almost
ll cells are alive. In Fig. 3B, which represents cells after 8-
zaguanine treatment, an increase in the percentage of cells in
arly stages of apoptosis and in later apoptotic/necrosis cell
eath was observed. These results are time, dose and cell type
ependent.
l
iodide (AV/IP) negative, as indicated by the arrow, in control conditions.
arly stage of apoptosis are Annexin V (AV) positive (A), and cells in late
tage of apoptosis or in necrosis are AV/IP positive (A/N).
CEM and MOLT3 cells surface expression of CD26,
ig. 4, increases after treatment with 8-azaguanine in a con-
entrations dependent manner. However as we can observe,
OLT3 cells have a higher basal surface CD26 expression
MFI) compared with that observed in CEM cells (18.7 ± 1.7
ersus 15.1 ± 2.6), submitted to the same experimental condi-
ions, although without significant difference. After MOLT3
-azaguanine treatment the expression of CD26 shows a sig-
ificant augmentation (18.7 ± 1.7 versus 65.4 ± 1.4).
In order to confirm how the mentioned results are due or
ot to the 8-azaguanine effect, we have incubated cells with
nother agent, the oxidative stress inducer hydrogen peroxide
n various concentrations (ranging from 10 to 200M) (data
ot shown), during 24 and 48 h and, after that, the expres-
ion of CD26 was analysed in cells submitted to 25М. No
ignificant change in CD26 cellular expression was observed
nder these new experimental conditions (Table 1).ected from the wells, where CEM and MOLT3 cells were
ncubated in the different conditions of the study, did not
M. Dourado et al. / Pathophysiology 14 (2007) 3–10 7
Fig. 4. Cell surface CD26 expression in human leukaemia cell lines CEM and MOLT3, before and after 48 h of 8-azaguanine treatment. Results are expressed
in mean fluorescence intensities (MFI). This value represents the medium fluorescence intensity detected in each cell, which is proportional to the number
of molecules labelled by the monoclonal antibody. As one can see, the expression of CD26 increased after treatment in a dose and cell type dependent
manner. For the same dose (25M) and incubation time (48 h) MOLT3 cells show a significant increase in CD26 expression, compared with CEM cells,
which may be related with a higher cellular sensitivity of MOLT3 cell to 8-azaguanine. *p < 0.05. (A) represents cell surface CD26 expression in CEM cell
line. (B) represents cell surface CD26 expression in MOLT3 cell line. (C) represents cell surface CD26 expression in CEM cells compared with MOLT3 cell
line.
Table 1
CEM and MOLT3 cells CD26 expression in control condition and after 8-
azaguanine (25M) and hydrogen peroxide (25M) treatment
Control Azag25 H2O2 25
CEM 15.1 ± 2.6 16.8 ± 6.0 14.1 ± 1.6
M
T
t
s
t
4
e
e
sOLT3 18.7 ± 1.7 65.4 ± 13 17.7 ± 1.3
he results are expressed in mean fluorescence intensity (MFI) and represent
he means ± S.D. of three separate experiments.
how any significant difference in our experimental condi-
ions, as we can observe in Fig. 5.
. DiscussionCD26/DPPIV is a broadly distributed molecule with sev-
ral functions in human cell physiology. It is constitutively
xpressed in a variety of different human cell types and tis-
ues, T-lymphocytes, epithelial cells of the intestine, prostate
F
M
tig. 5. DPPIV activity (U/L) in culture medium supernatant of CEM and
OLT3 cells cultured under control conditions and after 8-azaguanine
reated cells. No significant differences are seen.
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land and kidney proximal tubules. Its enzymatic activity is
etectable in serum, urine, seminal plasma, synovial fluid and
mniotic fluid. However, the origin of soluble DPPIV is not
ompletely understood [1,3,31,32].
Due to the presence of the soluble form of CD26/DPPIV in
erum, any peptide circulating in the blood carrying a proline
esidue in the penultimate N-terminal position is a candidate
ubstrate to its biological enzymatic activity. For instance,
egradation by DPPIV represents a rate-limiting step for the
ntestinal and renal transport of proline-containing peptides
13,18].
It has been demonstrated that CD26/DPPIV plays an
ssential role in immune regulation, particularly through its
nvolvement in T lymphocyte activation, being described as a
o-stimulatory molecule present in T lymphocyte surface, its
xpression being markedly enhanced following T lympho-
yte activation [28]. It has also been identified as the binding
rotein for ADA, an enzyme active in T lymphocyte that reg-
lates the levels of adenosine (Ado) and d-Ado by catalyzing
heir irreversible hydrolytic deamination, which further adds
o the importance of this membrane protein in T lymphocyte
rotection and activation [16,28,33,34].
CD26/DPPIV also appears to play a role in the devel-
pment or biological behaviour of selected human cancer
2,35,36]. Its potential contribution to the development of
uman haematological malignancies has been investigated
3,27,28,37–39], but its exact role in cancer biology remains
o be elucidated.
Preliminary results suggest that CD26 may contribute to
he biology of selected T-cell malignancies influencing the
rowth of tumour cell lines through its DPPIV activity. CD26
xpression has been described to be restricted to those patho-
ogical entities characterized by an aggressive clinical evolu-
ion such as T-cell acute lymphoblastic leukaemia (T-ALL)
nd T-cell CD30 positive anaplastic large-cell lymphoma sug-
esting a potential role for CD26 in the pathogenesis of these
alignancies [28,37,39].
T-cell lymphoid malignancies represent a heterogeneous
roup of diseases that are generally aggressive and often resis-
ant to current treatment modalities [28]. In fact, chemother-
py resistance is an impediment to the cancer therapies’
uccess.
In view of the multi-functional roles of CD26/DPPIV
n human body physiology, it is our hypothesis that
D26/DPPIV may be an appropriate target for novel treat-
ent modalities for T lymphocyte leukaemia. Sato and
ang[28] investigated the role of CD26/DPPIV expression
n cellular sensitivity to doxorubicin of human T leukaemia
ell line Jurkat and concluded that the CD26, especially
ts DPPIV enzymatic activity, results in enhanced cellular
ensitivity to DNA damage by doxorubicin. Authors con-
luded that it implies a potential role in the clinical setting
or CD26/DPPIV in the treatment of haematological malig-
ancies [28,38].
Our objective with this work was to contribute to the
larification of whether the expression of DPPIV/CD26
I
m
s
niology 14 (2007) 3–10
n leukaemia cell line in culture change, or not, after 8-
zaguanine treatment and what changes could we observed.
Present results showed that 8-azaguanine treatment reduce
ell viability in a time and dose dependent manner (Fig. 1).
orphological cellular changes consistent with apoptosis
as also observed. This cellular programmed cell death was
onfirmed by flow cytometry studies with AV/IP (Fig. 3).
Indeed the observed CEM cells morphological changes
Fig. 2) are related to apoptosis, as well as in MOLT3
ells (data not shown), namely cellular shrinking, cytoplasm
acuolation and blebing. Flow cytometry analysis of cell
eath demonstrated that the number of cells in early and
n late stages of apoptosis or in necrosis increase when
ncubated with 8-azaguanine in a time and dose dependent
anner. CEM and MOLT3 cells are acute leukaemia cell
ines, nevertheless MOLT3 reveals much more sensitivity to
-azaguanine effect than CEM. This result suggests that cyto-
oxicity induced by azaguanine is time, dose and cell type
ependent.
The analysis of CD26 expression demonstrated that 8-
zaguanine treated cells express more CD26 than the control
nes (not treated cells) do. After 8-azaguanine treatment,
here was an increase in the absolute number of cells express-
ng CD26 as well as in the number of expressed CD26
olecules/cell.
In presence of the observation that 8-azaguanine stimu-
ated CD26 expression and reduced cell viability it was our
bjective to investigate whether the cellular response can be
odified by other agents or not. For these we incubated cells
ith hydrogen peroxide, an oxidative stress inducer and anal-
sed the expression of CD26. CD26 expression did not show
ignificant difference in cells treated with hydrogen peroxide,
s it can be seen in Table 1. It seems reasonable to conclude
hat the modifications we observed are due to 8-azaguanine
ffects, in the experimental conditions of the study.
This CD26 over expression may contribute to the sensitiv-
ty of leukaemia cell lines to 8-azaguanine. That may lead to
uture treatment strategies targeting CD26 for selected human
ancers.
Nevertheless, DPPIV enzymatic activity in culture
edium did not show significant variation, neither with incu-
ation time, nor with different azaguanine concentration
Fig. 5). This implied that there could be discordance between
hese two parameters and that cell surface expression of CD26
an be disassociated from soluble levels of enzymatic DPPIV
ctivity, as others have mentioned before [7,29].
Our present study demonstrates that the membrane expres-
ion of CD26 and DPPIV enzymatic activity, soluble form,
eem to have no relation. This is, in accordance with others
tudies on Lymphoblastic HL-60 cell line, which suggested
hat a decrease in cell CD26 expression is not associated with
ncreased cleavage of DPPIV into the cultured medium [40].
t may be related to the fact that in these conditions the CD26
olecules expressed in the surface of the cells may be neces-
ary to play a key role in cancer cells and, therefore, it could
ot be released from cellular surface.
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Our present results showed augmented CD26 surface
xpression, after 8-azaguanine cell treatment. We suggest
hat this may be related to a biological active role for this
olecule, in T-ALL cell lines, since it follows the incubation
ime and seems related to 8-azaguanine cell pre treatment, as
t improved after it. The modification of CD26 expression is
ore evident in MOLT3 cell. This might reflect a contribu-
ion to improvement in the cellular sensitivity of this cell line
o 8-azaguanine. Thus, it could be a reflex of how different
ells with different molecular characteristics have different
reatment response to therapeutic agents, and in this way, it
enders a greater or lesser capacity to control the disease.
According to some authors, CD26/DPPIV may coexist
ith other molecules in human lymphocytes where it may
lay a direct or indirect role in pathophysiology of some
isease and therapeutic response [7]. Thus, modulation of
ts activity and expression might affect essential molecules
or cancer progression or intracellular signal transduction.
ecause T-cell lymphoid malignancies are generally aggres-
ive and resistant to current treatments, the development of
ew treatment approaches, based on a detailed understand-
ng of the molecular processes involved in the development
f cancer and chemotherapy response, would have potential
enefit.
In this work, our preliminary results demonstrated that
D26 cellular expression varies with chemotherapy treat-
ent, in a significant way, and is accompanied by a decrease
n cell viability. This may be related to cellular chemotherapy
esponse.
Although further work is required to elucidate the molec-
lar mechanisms of CD26/DPPIV in cancer cell biology, the
resent study suggests that CD26/DPPIV may become an
mportant marker of chemotherapy response.
We conclude that a better understanding of the molecular
echanisms underlying the action of DPPIV/CD26 would
elp determine how it influences normal cell function as
ell as pathological processes of cancer and chemotherapy
esponse and how it would be an appropriate target for novel
herapeutic intervention with conventional chemotherapy in
uman leukaemia.
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